Clinical Trial Supply and Logistics Market – Insights
Clinical trial supply and logistics is a management that is responsible for providing clinical supplies needed for clinical studies of drugs or medical devices in accordance with protocol and applicable regulatory requirements. This process involves oversight of the planning, packaging, forecasting, labeling, sourcing, distribution, and clinical supplies for government and commercial sponsors whose studies are in phase 1-4 clinical trials. Clinical trial suppliers integrate with many third party vendors and technicians to verify whether study drugs available are in sufficient quantity and quality at various stages of clinical distribution. This management, in terms of drug supply, offers full traceability from manufacturing to dispensation and destruction, which in turn reduces risks such as expiration or out of stock of products.
The global clinical trial supply and logistics market size was valued at US$ 14.95 Bn in 2017 and is expected to witness a CAGR of 7.1% over the forecast period (2018 – 2026).
Fig: Global Clinical Trial Supply and Logistics Market, By Region (US$ Mn)
Source: Coherent Market Insights Analysis (2018)
Clinical Trial Supply and Logistics Market Drivers
Quantity of ancillary supplies and diverse vendors to produce those supplies have significantly increased in the market, owing to rising demand for developing and producing clinical supplies from end user manufacturers or investigators for global studies in a cost-efficient manner. According to an article published in the Applied Clinical Trials website, 2016, there are around 40,000 unique investigators worldwide conducting at least one FDA-regulated clinical trial. Furthermore, increasing prevalence of cancer across the globe is providing new opportunities for global biopharmaceutical research community, and clinical trial supply and logistics management to bring the respective drug to the market sooner by navigating the complex clinical & regulatory environment. According to the World Health Organization (WHO), there were around 555,318 new cases of cancer in 2012 in the Middle East. The region is expected to witness around 961,098 cases by 2030, which will be the highest number of cancer cases among other regions in the world.
Change in regulations related to clinical trials is also expected to have some impact on the market. In 2013, the European Union enacted good distribution practices (GDPs), which are now becoming a globally adopted guidance. Although the timeline is still under discussion, new regulations for clinical trials that are conducted in the European Union will be revealed in 2019. The new regulations could potentially impact the supply chain, although it is primarily geared to existing good manufacturing practices (GMPs) for products covered by an existing directive.
Biologics are also expected to witness steady growth, owing to increasing research activities such as development of nanoparticle-based drug delivery systems in the field of genetics and biotechnology. For instance, in May 2018, Catalent Pharma Solutions collaborated with Valerius Biopharma AG, a Swiss biopharmaceutical company, for the development and manufacturing of Valerius’ biosimilar products, as alternatives to high-priced biologics. This is expected to boost clinical trial supply and logistics market growth over the forecast period.
Clinical Trial Supply and Logistics Market Regional Outlook
On the basis of region, the global clinical trial supply and logistics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold a dominant position in this market, owing to the adoption of technologically advanced products, well established regulatory agencies, and presence of major Contract Research Organizations (CRO’s) and biopharmaceutical company’s hubs. Moreover, factors such as improved healthcare facilities and better reimbursement scenario are also driving growth of clinical trial supply and logistics market in this region. The number of new vendors trying to enter the healthcare industry are expected to increase over the forecast period, as there are many niche market players trying to leverage the market share through new inventories in medical devices and drugs. Also, they will require clinical trial supply management to cut down costs across all aspects of the business, by reducing internal capacity - in terms of site maintenance and employee headcount. Thus, emerging economies such as Asia Pacific and Latin America has huge potential for market growth, and is projected to be the fastest growing region over the forecast period.
Some of the key players operating in the global clinical trial supply and logistics market include Catalent Pharma Solutions, Inc., Almac Group, Movianto, Patheon, Inc., PCI Pharma Distribution, Sharp Packaging Distribution, PAREXEL International Corporation, Marken, KLIFO A/S, and Biocair.
Continuous emphasis by the manufacturers towards balancing shipment and supply costs, optimizing production and packaging and minimizing overage and avoiding shortages, are propelling the demand for efficient solutions for clinical trial supply and logistics. Technological advancements will also drive the growth in clinical trial supply and logistics market, providing efficient planning and real-time data analysis to improve supply chains mid-trial. Drug pooling for multi-trial programmes will also augment the demand for regional depot network with strong transport networks to trial sites.
Increase in number of registered clinical trials across the regions is also expected to spur the demand of clinical trial supply and logistics market during the forecast period. Various online sources suggest that the Brazil holds the second most registered clinical trials among the BRIC (Brazil, Russia, India and China) countries, with a share of approximately 2% of the global volume. Furthermore, vendors are also focussing on launching different clinical programs to market their services and attract more clients and government to partnership with them. For instance, in June 2018, Bionical Group Ltd launched Bionical-Clinical Early Access Programs (EAP) which connect established and successful Clinical Research Organization to support large and small scale Pharma and Biotech industries enabling, appropriate treatment access to patients in desperate need.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients